Assets
| Type | Time | Amount | Unit |
|---|---|---|---|
| ifrs-full:Assets | 2018-12-31 | 440876000 | vDKK |
| ifrs-full:Assets | 2019-12-31 | 180754000 | vDKK |
| ifrs-full:Assets | 2018-12-31 | 441349000 | vDKK |
| ifrs-full:Assets | 2019-12-31 | 180237000 | vDKK |
Revenue
| Type | Start date | End date | Amount | Unit |
|---|
XML
See the xml submitted here:
XML: http://regnskaber.virk.dk/55366223/amNsb3VkczovLzAzLzFhL2VmLzNjLzM3LzI0MjUtNDk5YS1hOGUzLWJmMTA2ZjE3NDlmOA.xml
Separator
The full data:
<?xml version="1.0" encoding="UTF-8"?><!-- Version: 1.1.868.0 --><!-- Document created: 24-03-2020 08:32:35 --><!-- Created by: XBRL Wizard, EasyX --><xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:entry04-ifrs-dk_2019-12-20="http://xbrl.dcca.dk/ifrs-dk/entry04-ifrs-dk_2019-12-20" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2014-03-05/ifrs-full" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:info="http://xbrl.iasb.org/info" xmlns:ifrs-mc="http://xbrl.ifrs.org/taxonomy/2014-03-05/ifrs-mc" xmlns:rol_ifrs-dk_105.00_2019-12-20="http://xbrl.dcca.dk/role/ifrs-dk/rol_ifrs-dk_105.00_2019-12-20" xmlns:tch="http://xbrl.dcca.dk/tch" xmlns:gen="http://xbrl.org/2008/generic" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:entry="http://entry" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:reference="http://xbrl.org/2008/reference" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:cmn="http://xbrl.dcca.dk/cmn" xmlns:label="http://xbrl.org/2008/label" xmlns:rol_ifrs-dk_110.00_2019-12-20="http://xbrl.dcca.dk/role/ifrs-dk/rol_ifrs-dk_110.00_2019-12-20" xmlns:rol_ifrs-dk_210.00_2019-12-20="http://xbrl.dcca.dk/role/ifrs-dk/rol_ifrs-dk_210.00_2019-12-20" xmlns:rol_ifrs-dk_310.00_2019-12-20="http://xbrl.dcca.dk/role/ifrs-dk/rol_ifrs-dk_310.00_2019-12-20" xmlns:rol_ifrs-dk_330.00_2019-12-20="http://xbrl.dcca.dk/role/ifrs-dk/rol_ifrs-dk_330.00_2019-12-20" xmlns:rol_ifrs-dk_410.00_2019-12-20="http://xbrl.dcca.dk/role/ifrs-dk/rol_ifrs-dk_410.00_2019-12-20" xmlns:rol_ifrs-dk_520.00_2019-12-20="http://xbrl.dcca.dk/role/ifrs-dk/rol_ifrs-dk_520.00_2019-12-20" xmlns:rol_ifrs-dk_610.00_2019-12-20="http://xbrl.dcca.dk/role/ifrs-dk/rol_ifrs-dk_610.00_2019-12-20" xmlns:rol_ifrs-dk_710.00_2019-12-20="http://xbrl.dcca.dk/role/ifrs-dk/rol_ifrs-dk_710.00_2019-12-20" xmlns:rol_ifrs-dk_8NN.NN_2019-12-20="http://xbrl.dcca.dk/role/ifrs-dk/rol_ifrs-dk_8NN.NN_2019-12-20" xmlns:rol_dim="http://xbrl.ifrs.org/role/ifrs/dimensions" xmlns:ifrs-dk="http://xbrl.dcca.dk/ifrs-dk-cor_2019-12-20" xmlns:entry-sob="http://xbrl.dcca.dk/entry-sob" xmlns:sob="http://xbrl.dcca.dk/sob" xmlns:rol_sob_300.00_2019-12-20="http://xbrl.dcca.dk/role/sob/rol_sob_300.00_2019-12-20" xmlns:cmn_rol="http://archprod.service.eogs.dk/taxonomy/20191220/cmn_rol.xsd" xmlns:rol_mrv_2019-12-20="http://xbrl.dcca.dk/role/mrv/rol_mrv_2019-12-20" xmlns:tax="http://xbrl.dcca.dk/tax" xmlns:gsd="http://xbrl.dcca.dk/gsd" xmlns:dst="http://xbrl.dcca.dk/dst" xmlns:ifrs-temp-entry="http://ifrs-temp-entry" xmlns:fsa="http://xbrl.dcca.dk/fsa" xmlns:rol_ps_mc_2014-03-05="http://xbrl.ifrs.org/role/ifrs/rol_ps_mc_2014-03-05" xmlns:mrv="http://xbrl.dcca.dk/mrv" xmlns:entry-mrv="http://xbrl.dcca.dk/entry-mrv" xmlns:mrvcsr="http://xbrl.dcca.dk/mrvcsr" xmlns:entry-gsd="http://xbrl.dcca.dk/entry-gsd" xmlns:ca="http://xbrl.org/2008/assertion/consistency" xmlns:fn="http://www.w3.org/2005/xpath-functions" xmlns:variable="http://xbrl.org/2008/variable" xmlns:xfi="http://www.xbrl.org/2008/function/instance" xmlns:cf="http://xbrl.org/2008/filter/concept" xmlns:valm="http://xbrl.org/2010/message/validation" xmlns:ea="http://xbrl.org/2008/assertion/existence" xmlns:rol_gsd_000.00_2019-12-20="http://xbrl.dcca.dk/role/gsd/rol_gsd_000.00_2019-12-20" xmlns:validation="http://xbrl.org/2008/validation" xmlns:formula="http://xbrl.org/2008/formula" xmlns:msg="http://xbrl.org/2010/message" xmlns:va="http://xbrl.org/2008/assertion/value" xmlns:entry-arr="http://xbrl.dcca.dk/entry-arr" xmlns:arr="http://xbrl.dcca.dk/arr" xmlns:rol_arr_1NN.NN_2019-12-20="http://xbrl.dcca.dk/role/arr/rol_arr_1NN.NN_2019-12-20" xmlns:rol_ifrs-dk_510.00_2019-12-20="http://xbrl.dcca.dk/role/ifrs-dk/rol_ifrs-dk_510.00_2019-12-20" xsi:schemaLocation="http://xbrl.org/2006/xbrldi http://www.xbrl.org/2006/xbrldi-2006.xsd">
<link:schemaRef xlink:type="simple" xlink:href="http://archprod.service.eogs.dk/taxonomy/20191220/ifrs/entry-ifrs-dk_04_IS-ByFunction_SFP-CurrentNoncurrent_OCI-NetOfTax_CF-IndirectMethod_2019-12-20.xsd"/>
<xbrli:context id="ctx1">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">32266355</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="ctx2">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">32266355</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="ctx3">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">32266355</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis">ifrs-full:SeparateMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx4">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">32266355</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis">ifrs-full:SeparateMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx5">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">32266355</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="ctx6">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">32266355</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="ctx7">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">32266355</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis">ifrs-full:SeparateMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx8">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">32266355</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis">ifrs-full:SeparateMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx9">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">32266355</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="ifrs-dk:IdentificationOfComponentOfCashFlowsFromUsedInOperatingActivitiesDimension">
<ifrs-dk:componentOfCashFlowsIdentifier>0</ifrs-dk:componentOfCashFlowsIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx10">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">32266355</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="ifrs-dk:IdentificationOfComponentOfCashFlowsFromUsedInOperatingActivitiesDimension">
<ifrs-dk:componentOfCashFlowsIdentifier>1</ifrs-dk:componentOfCashFlowsIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx11">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">32266355</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis">ifrs-full:SeparateMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="ifrs-dk:IdentificationOfComponentOfCashFlowsFromUsedInOperatingActivitiesDimension">
<ifrs-dk:componentOfCashFlowsIdentifier>2</ifrs-dk:componentOfCashFlowsIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx12">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">32266355</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis">ifrs-full:SeparateMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="ifrs-dk:IdentificationOfComponentOfCashFlowsFromUsedInOperatingActivitiesDimension">
<ifrs-dk:componentOfCashFlowsIdentifier>3</ifrs-dk:componentOfCashFlowsIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx13">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">32266355</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="ifrs-dk:IdentificationOfComponentOfCashFlowsFromUsedInOperatingActivitiesDimension">
<ifrs-dk:componentOfCashFlowsIdentifier>4</ifrs-dk:componentOfCashFlowsIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx14">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">32266355</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="ifrs-dk:IdentificationOfComponentOfCashFlowsFromUsedInOperatingActivitiesDimension">
<ifrs-dk:componentOfCashFlowsIdentifier>5</ifrs-dk:componentOfCashFlowsIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx15">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">32266355</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis">ifrs-full:SeparateMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="ifrs-dk:IdentificationOfComponentOfCashFlowsFromUsedInOperatingActivitiesDimension">
<ifrs-dk:componentOfCashFlowsIdentifier>6</ifrs-dk:componentOfCashFlowsIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx16">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">32266355</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis">ifrs-full:SeparateMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="ifrs-dk:IdentificationOfComponentOfCashFlowsFromUsedInOperatingActivitiesDimension">
<ifrs-dk:componentOfCashFlowsIdentifier>7</ifrs-dk:componentOfCashFlowsIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx17">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">32266355</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="ifrs-dk:IdentificationOfComponentOfCashFlowsFromUsedInOperatingActivitiesDimension">
<ifrs-dk:componentOfCashFlowsIdentifier>8</ifrs-dk:componentOfCashFlowsIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx18">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">32266355</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="ifrs-dk:IdentificationOfComponentOfCashFlowsFromUsedInOperatingActivitiesDimension">
<ifrs-dk:componentOfCashFlowsIdentifier>9</ifrs-dk:componentOfCashFlowsIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx19">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">32266355</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis">ifrs-full:SeparateMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="ifrs-dk:IdentificationOfComponentOfCashFlowsFromUsedInOperatingActivitiesDimension">
<ifrs-dk:componentOfCashFlowsIdentifier>10</ifrs-dk:componentOfCashFlowsIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx20">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">32266355</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis">ifrs-full:SeparateMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="ifrs-dk:IdentificationOfComponentOfCashFlowsFromUsedInOperatingActivitiesDimension">
<ifrs-dk:componentOfCashFlowsIdentifier>11</ifrs-dk:componentOfCashFlowsIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx21">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">32266355</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis">ifrs-full:SeparateMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="ifrs-dk:IdentificationOfComponentOfCashFlowsFromUsedInInvestingActivitiesDimension">
<ifrs-dk:componentOfCashFlowsIdentifier>0</ifrs-dk:componentOfCashFlowsIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx22">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">32266355</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis">ifrs-full:SeparateMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="ifrs-dk:IdentificationOfComponentOfCashFlowsFromUsedInInvestingActivitiesDimension">
<ifrs-dk:componentOfCashFlowsIdentifier>1</ifrs-dk:componentOfCashFlowsIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx23">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">32266355</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-01-01</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="ctx24">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">32266355</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-01-01</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="ctx25">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">32266355</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-01-01</xbrli:instant>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis">ifrs-full:SeparateMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx26">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">32266355</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-01-01</xbrli:instant>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="ifrs-full:ConsolidatedAndSeparateFinancialStatementsAxis">ifrs-full:SeparateMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx27">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">32266355</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardAxis">
<cmn:memberOfBoardIdentifier>0</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx28">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">32266355</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardAxis">
<cmn:memberOfBoardIdentifier>1</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx29">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">32266355</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardAxis">
<cmn:memberOfBoardIdentifier>2</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx30">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">32266355</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardAxis">
<cmn:memberOfBoardIdentifier>3</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx31">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">32266355</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardAxis">
<cmn:memberOfBoardIdentifier>4</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx32">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">32266355</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardAxis">
<cmn:memberOfBoardIdentifier>5</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx33">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">32266355</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardAxis">
<cmn:memberOfBoardIdentifier>6</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx34">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">32266355</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardAxis">
<cmn:memberOfBoardIdentifier>7</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx35">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">32266355</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfExecutiveBoardAxis">
<cmn:memberOfBoardIdentifier>0</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx36">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">32266355</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfExecutiveBoardAxis">
<cmn:memberOfBoardIdentifier>1</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx37">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">32266355</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfAuditorDimension">
<cmn:auditorIdentificer>0</cmn:auditorIdentificer>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx38">
<xbrli:entity>
<xbrli:identifier scheme="http://www.dcca.dk/cvr">32266355</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:typedMember dimension="cmn:IdentificationOfAuditorDimension">
<cmn:auditorIdentificer>1</cmn:auditorIdentificer>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:unit id="vDKK">
<xbrli:measure>iso4217:DKK</xbrli:measure>
</xbrli:unit>
<xbrli:unit id="share">
<xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit>
<gsd:NameOfReportingEntity contextRef="ctx1" xml:lang="da">Orphazyme A/S</gsd:NameOfReportingEntity>
<gsd:IdentificationNumberCvrOfReportingEntity contextRef="ctx1">32266355</gsd:IdentificationNumberCvrOfReportingEntity>
<gsd:AddressOfReportingEntityStreetName contextRef="ctx1" xml:lang="da">c/o COBIS A/S, Ole Maaløes Vej</gsd:AddressOfReportingEntityStreetName>
<gsd:AddressOfReportingEntityStreetBuildingIdentifier contextRef="ctx1" xml:lang="da">3</gsd:AddressOfReportingEntityStreetBuildingIdentifier>
<gsd:AddressOfReportingEntityPostCodeIdentifier contextRef="ctx1" xml:lang="da">DK-2200</gsd:AddressOfReportingEntityPostCodeIdentifier>
<gsd:AddressOfReportingEntityDistrictName contextRef="ctx1" xml:lang="da">Copenhagen N</gsd:AddressOfReportingEntityDistrictName>
<gsd:AddressOfReportingEntityCountry contextRef="ctx1" xml:lang="da">Denmark</gsd:AddressOfReportingEntityCountry>
<gsd:ReportingPeriodStartDate contextRef="ctx1">2019-01-01</gsd:ReportingPeriodStartDate>
<gsd:ReportingPeriodEndDate contextRef="ctx1">2019-12-31</gsd:ReportingPeriodEndDate>
<gsd:DateOfGeneralMeeting contextRef="ctx1">2020-03-26</gsd:DateOfGeneralMeeting>
<gsd:NameAndSurnameOfChairmanOfGeneralMeeting contextRef="ctx1" xml:lang="da">Rikke Schiøtt Petersen</gsd:NameAndSurnameOfChairmanOfGeneralMeeting>
<gsd:NameOfFinancialInstitution contextRef="ctx1" xml:lang="da">Danske Bank</gsd:NameOfFinancialInstitution>
<gsd:AddressOfFinancialStreetName contextRef="ctx1" xml:lang="da">Holmens Kanal</gsd:AddressOfFinancialStreetName>
<gsd:AddressOfFinancialStreetBuildingIdentifier contextRef="ctx1" xml:lang="da">2-12</gsd:AddressOfFinancialStreetBuildingIdentifier>
<gsd:AddressOfFinancialPostCodeIdentifier contextRef="ctx1" xml:lang="da">DK-1092</gsd:AddressOfFinancialPostCodeIdentifier>
<gsd:AddressOfFinancialDistrictName contextRef="ctx1" xml:lang="da">Copenhagen K</gsd:AddressOfFinancialDistrictName>
<gsd:NameOfLawFirm contextRef="ctx1" xml:lang="da">Gorrissen Federspiel, Advokatpartnerselskab</gsd:NameOfLawFirm>
<gsd:AddressOfLawFirmStreetName contextRef="ctx1" xml:lang="da">Axeltorv</gsd:AddressOfLawFirmStreetName>
<gsd:AddressOfLawFirmStreetBuildingIdentifier contextRef="ctx1" xml:lang="da">2</gsd:AddressOfLawFirmStreetBuildingIdentifier>
<gsd:AddressOfLawFirmPostCodeIdentifier contextRef="ctx1" xml:lang="da">DK-1609</gsd:AddressOfLawFirmPostCodeIdentifier>
<gsd:AddressOfLawFirmDistrictName contextRef="ctx1" xml:lang="da">Copenhagen V</gsd:AddressOfLawFirmDistrictName>
<mrv:CorporateGovernanceReport contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="5">CORPORATE GOVERNANCE</td></tr><tr><td colspan="5">In order to maintain the trust of the Companyâs stakeholders, Orphazyme is committed to ensuring transparent and good corporate governance. As a company listed on Nasdaq Copenhagen, Orphazyme is subject to the Recommendations on Corporate Governance from November 2017.</td></tr><tr><td colspan="5">The Recommendations on Corporate Governance are best practice guidelines for the management of companies admitted to trading on a regulated market.</td></tr><tr><td colspan="5">Orphazyme intends to comply with the Recommendations on Corporate Governance in all material respects, however, due to the current size of the Company and the nature of its present operations, the company has opted to deviate from the recommendations in the following areas</td></tr><tr><td colspan="5">â¢Â  Orphazyme has decided to only publish annual reports and half-yearly financial reports;</td></tr><tr><td colspan="5">â¢Â  the annual report does not include information on individual board members' participation in board meetings;</td></tr><tr><td colspan="5">â¢Â  the general conclusion of the latest evaluation of the Board of Directors is not described in the annual report, but is accounted for by the Chairman at the annual general meeting;</td></tr><tr><td colspan="5">â¢Â  share-based remuneration is offered to the Board of Directors;</td></tr><tr><td colspan="5">â¢Â  share-based instruments be granted to board members shall have a maturity of one year from the date of allocation;</td></tr><tr><td colspan="5">â¢Â  the Chief Executive Officer may under certain circumstances be entitled to receive remuneration related to the notice period, including severance pay, which exceeds two years' total remuneration; and</td></tr><tr><td colspan="5">â¢Â  Orphazyme has decided not to prepare a remuneration report until the company is required to do so pursuant to section 139(b) of the Danish Companies Act.</td></tr><tr><td colspan="5">Orphazyme's corporate governance statement includes a summary of the Company's governance structure, a description of internal control and financial reporting procedures, Orphazyme's position on the Recommendation on Corporate Governance as well as a complete list of the Company's comments to recommendations that the Company opted to deviate from.</td></tr><tr><td colspan="5">The corporate governance statement is available on www.orphazyme.com.</td></tr><tr><td colspan="5">Coporate Governance Statement</td></tr><tr><td colspan="5">https://orphazyme.gcs-web.com/corporate-governance/highlights</td></tr><tr><td colspan="5">BOARD OF DIRECTORS</td></tr><tr><td>Name</td><td>Position</td><td>Independent(1)</td><td>Year of first appointment</td><td>Expiration of term</td></tr><tr><td>Georges Gemayel</td><td>Chairman</td><td>Independent</td><td>2012</td><td>2020</td></tr><tr><td>Bo Jesper Hansen</td><td>Deputy Chairman</td><td>Independent</td><td>2010</td><td>2020</td></tr><tr><td>Martin Bonde</td><td>Member</td><td>Independent</td><td>2010</td><td>2020</td></tr><tr><td>Sten Verland</td><td>Member</td><td>Independent</td><td>2010</td><td>2020</td></tr><tr><td>Rémi Droller</td><td>Member</td><td>Independent</td><td>2015</td><td>2020</td></tr><tr><td>Martijn Kleijwegt</td><td>Member</td><td>Independent</td><td>2017</td><td>2020</td></tr><tr><td>Catherine Moukheibir</td><td>Member</td><td>Independent</td><td>2017</td><td>2020</td></tr><tr><td>Anders Hedegaard</td><td>Member</td><td>Independent</td><td>2017</td><td>2020</td></tr><tr><td colspan="5">1) The Company has based its assessment of independence on the basis of criteria set out in the current Coporate Governance Recommendations (as defined below).</td></tr><tr><td colspan="5">BOARD OF DIRECTORS</td></tr><tr><td colspan="5">The Board of Directors is responsible for the overall and strategic management and proper organization of Orphazymeâs business and operations and it supervises the Companyâs activities, management, and organization. The Board of Directors appoints and dismisses the members of the Executive Management, who are responsible for the day-to-day management of the Company.</td></tr><tr><td colspan="5">The Board of Directors normally holds at least five regular meetings annually, including a strategy review, plus ad-hoc meetings as required. Extraordinary board meetings are convened by the Chairman when necessary or when requested by a member of the Board of Directors, a member of the Executive Management, or by the Companyâs auditor. The Board of Directors forms a quorum when more than half of its members are represented, including the Chairman or the Deputy Chairman. Resolutions of the Board of Directors are passed by a simple majority of the votes present at the meeting. In the event of equal votes, the Chairman or, in his absence, the Deputy Chairman shall have the casting vote. The Board of Directors conducts an annual evaluation of the effectiveness, performance, achievements, and competencies of the Board of Directors and of the individual members as well as the collaboration with the Executive Management.</td></tr><tr><td colspan="5">The members of the Board of Directors elected by the general meeting are elected for a term of one year. Members of the Board of Directors may be re-elected.</td></tr><tr><td colspan="5">The Company believes that the members of the Board of Directors possess the professional skills and experience required to serve as board members of the Company.</td></tr><tr><td colspan="5">BOARD COMMITTEES</td></tr><tr><td colspan="5">To support the Board of Directors in its duties, the Board of Directors has established and appointed an Audit Committee, a Nomination Committee, and a Remuneration Committee. These committees are charged with reviewing issues pertaining to their respective fields that are due to be considered at board meetings. Written charters specifying the tasks and responsibilities for each of the committees are available on the Companyâs website www.orphazyme.com.</td></tr><tr><td colspan="5">Comittee Charters Summary</td></tr><tr><td colspan="5">https://orphazyme.gcs-web.com/corporate-governance/highlights</td></tr><tr><td colspan="5">AUDIT COMMITTEE</td></tr><tr><td colspan="5">The Audit Committee reviews accounting and audit matters that by decision of the Board of Directors or the Audit Committee require a more thorough evaluation, and assess the internal controls and risk management systems of Orphazyme. Its duties also include supervision of the Companyâs auditors and review of the audit process. In accordance with the Recommendations on Corporate Governance of the Danish Committee on Corporate Governance issued in November 2017 (the âCorporate Governance Recommendationsâ), the Company has decided that the Chairman of the Board of Directors may not also be the Chairman of the Audit Committee and that a majority of the members of the Audit Committee are required to meet the independence requirements set out in the Corporate Governance Recommendations. In addition, at least one member shall have accounting or audit qualifications and between them, the members shall possess such expertise and experience as to provide an updated insight into, and experience in, the financial, accounting, and audit aspects of companies with shares admitted to trading and official listing on a regulated market.</td></tr><tr><td colspan="5">The Audit Committee shall consist of no less than three members appointed by and among the Board of Directors, including the Chairman of the Audit Committee, and consists of Catherine Moukheibir as Chairman, Martijn Kleijwegt, and Sten Verland. All of the members of the Audit Committee meet the independence requirement set out in the Corporate Governance Recommendations. The Chief Executive Officer and/or the Chief Financial Officer and the Companyâs external auditor shall participate in meetings of the Audit Committee if so requested by the Audit Committee and the external auditor shall attend at least one meeting per year or the relevant part hereof where the Executive Management is not present.</td></tr><tr><td colspan="5">NOMINATION COMMITTEE</td></tr><tr><td colspan="5">The Nomination Committee shall assist the Board of Directors with ensuring that appropriate plans and processes are in place for the nomination of candidates to the Board of Directors, the Executive Management, and the board committees. Moreover, the Nomination Committee shall evaluate the composition of the Board of Directors and the Executive Management. This includes making recommendations for nomination or appointment of members of (a) the Board of Directors, (b) the Executive Management, and (c) the board committees established by the Board of Directors.</td></tr><tr><td colspan="5">The Nomination Committee consists of no less than three members appointed by and among the Board of Directors, including Georges Gemayel as Chairman, Martin Bonde, and Sten Verland. All of the members of the Nomination Committee meet the independence requirements set out in the Corporate Governance Recommendations.</td></tr><tr><td colspan="5">REMUNERATION COMMITTEE</td></tr><tr><td colspan="5">The Remuneration Committee ensures that the Company maintains a Remuneration Policy for the members of the Board of Directors and the Executive Management, and to evaluate and make recommendations for the remuneration of the members of the Board of Directors and the Executive Management.</td></tr><tr><td colspan="5">The Remuneration Committee shall consist of no less than three members appointed by and among the Board of Directors, including Bo Jesper Hansen as Chairman, Rémi Droller, and Anders Hedegaard. All of the members of the Remuneration Committee meet the independence requirements set out in the Corporate Governance Recommendations.</td></tr><tr><td colspan="5">DESCRIPTION OF INTERNAL CONTROL AND FINANCIAL REPORTING PROCEDURES</td></tr><tr><td colspan="5">The Board of Directors, the Audit Committee, and the Executive Management are ultimately responsible for Orphazymeâs risk management and internal controls in relation to its financial reporting and approve Orphazymeâs general policies in that regard. The Audit Committee assists the Board of Directors in overseeing the reporting process and the most important risks involved in this respect. The Executive Management is responsible for the effectiveness of the internal controls and risk management and for the implementation of such controls aimed at mitigating the risk associated with the financial reporting. Orphazyme has internal control and financial reporting procedures aimed at enabling it to monitor its performance, operations, funding, and risk.</td></tr></table></mrv:CorporateGovernanceReport>
<mrv:StatementOfCorporateSocialResponsibility contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">CORPORATE SOCIAL RESPONSIBILITY</td></tr><tr><td colspan="1">As a biopharmaceutical company, we are aware of our responsibilities towards society, patients, stakeholders, and employees and we believe that our corporate behavior should always be of the highest ethical standard. When conducting our business, we strive to demonstrate respect for key moral principles and comply with international regulations and good practice guidelines to make sure that our product is safe and meets strict quality guidelines. As most of our business activities are outsourced, we work closely with our partners to ensure compliance with these regulations and guidelines.</td></tr><tr><td colspan="1">We believe that our ethical behavior strengthens Orphazymeâs status as an attractive workplace for both current and future employees.</td></tr><tr><td colspan="1">Diversity Policy</td></tr><tr><td colspan="1">https://orphazyme.gcs-web.com/corporate-governance/highlights</td></tr><tr><td colspan="1">BUSINESS MODEL</td></tr><tr><td colspan="1">Orphazyme is a Danish biopharmaceutical company with approximately 90 employees. The office in Copenhagen serves as headquarters and focuses on coordination and execution of the drug development process and on administration of preclinical and clinical trials.</td></tr><tr><td colspan="1">We are pioneering the Heat-Shock Protein (HSP) response for rare, neurodegenerative diseases. The key activity of Orphazyme is to develop innovative therapies for orphan diseases characterized by protein misfolding where we can apply our specialized know-how in HSPs. Our objective is to successfully conduct and complete the planned and ongoing trials of arimoclomol for the treatment of Niemann-Pick disease Type C (NPC), sporadic Inclusion Body Myositis (sIBM), Amyotrophic Lateral Sclerosis (ALS), and Gaucher disease. We use external suppliers in order to both manufacture and tabletize the medicine, as well as for distribution.</td></tr><tr><td colspan="1">RISK ANALYSIS</td></tr><tr><td colspan="1">Risk is defined as the potential negative effect that can be experienced by the business or any of Orphazymeâs stakeholders. Risk is seen as a combination between impact and likelihood of any given subject. Orphazymeâs potential risk of impacting social and employee conditions, human rights, and anti-corruption is estimated to be limited, mainly due to the strictly regulated business environment the company operates in. Orphazymeâs potential risk of impacting the environment and climate is estimated to be very limited mainly as a result of the modest number of employees and the use of external suppliers for all production. Orphazyme has prepared a policy for social and employee conditions, human rights, and anti-corruption. Insofar as a specific risk has been identified in any of these areas, it will be addressed by the relevant policy.</td></tr><tr><td colspan="1">CSR REPORTING AREAS</td></tr><tr><td colspan="1">ENVIRONMENT AND CLIMATE</td></tr><tr><td colspan="1">Orphazyme does not have Environment or Climate policies. The Company acknowledges the challenges linked to climate change, and as a result Orphazyme operates an office focused on efficient management of office materials. However, based on the fact that the Company is operating from rented offices and conducts its business in a highly regulated industry and climate, Orphazymeâs potential impact on the environment and climate is viewed as minimal. As a result, specific Environment and Climate policies have not been developed at this time.</td></tr><tr><td colspan="1">HUMAN RIGHTS</td></tr><tr><td colspan="1">Policies</td></tr><tr><td colspan="1">Orphazyme acknowledges and supports the maintenance of internationally declared human rights and bases its work on the UN Universal Declaration of Human Rights and the interpretation that it is the responsibility of the State to protect, and the companiesâ responsibility to respect these rights.</td></tr><tr><td colspan="1">Orphazyme conducts its business in accordance with the ethical and scientific principles governing clinical research on human subjects, as set out in the Declaration of Helsinki and the International Conference on Harmonization (ICH) guidelines on Good Clinical Practice (GCP).</td></tr><tr><td colspan="1">Orphazyme interprets human rights to comprise respect for diversity. Therefore, it is the aim of the Company to ensure that employees have the possibility to function in a workplace without harassment regardless of gender, age, race, religion, or ethnicity.</td></tr></table><br><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Activities and results</td></tr><tr><td colspan="1">All protocols in 2019 have been carried out in accordance with the current ICH-GCP guidelines. Furthermore, since 2018, Orphazyme has included in its supplier contracts a new condition that requires all suppliers to comply with the Declaration of Helsinki.</td></tr><tr><td colspan="1">Orphazyme has a whistleblower policy in order to allow reporting of potential violations of the respect for diversity in the workplace. The policy was established in 2018 and mandatory meetings are held annually for all employees. In 2019, there have been no reports via the whistbleblower scheme concerning violations of the respect for diversity in the workplace or other human rights violations.</td></tr><tr><td colspan="1">ANTI-CORRUPTION AND BRIBERY</td></tr><tr><td colspan="1">Policies</td></tr><tr><td colspan="1">Orphazyme is committed to maintaining the highest standards of ethical conduct and will not tolerate the use of bribery or corruption to achieve its business objectives. Employees must decline any expensive gifts, money, trips, or other such offerings from business contacts. This also includes receiving services from suppliers without paying for them.</td></tr></table><br><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Activities and results</td></tr><tr><td colspan="1">Orphazyme has a whistleblower policy in order to allow reporting of potential violations of laws and serious violations of internal policies and procedures, including fraud and anti-corruption. The policy was established in 2018 and mandatory joint meetings are held annually for all employees. Orphazyme continued, via its Employee Handbook, to familiarize all new employees with the company policies regarding anti-corruption.</td></tr><tr><td colspan="1">Orphazyme only enters into agreements with consultants that have signed the acknowledgement of Orphazymeâs commitment to maintaining the highest standards of ethical conduct.</td></tr><tr><td colspan="1">Orphazyme has not identified any cases of anti-corruption or bribery incidents throughout the year nor have any incidents been reported via the whistleblower scheme.</td></tr><tr><td colspan="1">SOCIAL AND STAFF MATTERS</td></tr><tr><td colspan="1">The office in Copenhagen serves as our headquarters and focuses on coordination and execution of the drug development process and on the conduct of preclinical and clinical trials administration. As of December 31, 2019, the organization comprised</td></tr><tr><td colspan="1">â¢Â  Senior Management (5 persons comprising Executive Management and Key Employees)</td></tr><tr><td colspan="1">â¢Â  Administration (6 persons)</td></tr><tr><td colspan="1">â¢Â  Clinical development (42 persons)</td></tr><tr><td colspan="1">â¢Â  Chemistry, manufacturing, and controls/ quality assurance (2 persons)</td></tr><tr><td colspan="1">â¢Â  Regulatory (6 persons)</td></tr><tr><td colspan="1">â¢Â  Research (19 persons)</td></tr><tr><td colspan="1">â¢Â  Finance, legal, and IT (6 persons)</td></tr></table><br><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="5">Activities and results</td></tr><tr><td colspan="5">In 2019, Orphazyme continued to actively encourage all potential employees to apply for employment opportunities, irrespective of gender, age, race, religion, or ethnicity. Moreover, Orphazyme continues to introduce all new employees to the Employee Handbook in order to ensure a workplace that respects diversity and other values inherent in the Company.</td></tr><tr><td colspan="5">In 2019, Orphazyme continued its efforts to offer its employees opportunities for personal learning and development by providing internal training as well as external continuing education courses. The Company maintains its focus on a healthy work-life balance by encouraging employees to take all holidays to which they are entitled, and by providing opportunities such as working from home if needed. Furthermore, in 2019 Orphazyme continued to promote a healthy lifestyle by offering weekly employer-paid exercise options.</td></tr><tr><td colspan="5">In 2019, Orphazyme has been able to retain a highly satisfactory employee turnover rate.</td></tr><tr><td colspan="5">KEY EMPLOYEE RATIOS</td></tr><tr><td /><td>2019</td><td>2019</td><td>2018</td><td>2018</td></tr><tr><td /><td>Male</td><td>Female</td><td>Male</td><td>Female</td></tr><tr><td>Orphazyme A/S</td><td>35%</td><td>65%</td><td>35%</td><td>65%</td></tr><tr><td>Executive Management and Key Employees</td><td>80%</td><td>20%</td><td>100%</td><td>0%</td></tr><tr><td>Director level and above</td><td>33%</td><td>67%</td><td>30%</td><td>70%</td></tr><tr><td>Below director level</td><td>31%</td><td>69%</td><td>29%</td><td>71%</td></tr></table></mrv:StatementOfCorporateSocialResponsibility>
<mrv:StatementOfTargetFiguresAndPoliciesForTheUnderrepresentedGender contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Policies.</td></tr><tr><td colspan="1">Orphazyme A/S knows that all employees are critical to the success of the Company and its programs. The Company is a diverse workplace committed to maintaining a working environment that is free of discrimination, harassment, and bullying. Orphazyme views diversity as an integrated part of a socially responsible company. In accordance with applicable law, we have adopted a Diversity Policy, which sets out our goals for increasing the diversity in the Board of Directors and at other management levels. We encourage diversity, including age, ethnicity, nationality, religion, education, and skills. Currently, our staff consists of 65.5% females and 34.6% males, including 67% female and 33% male employees at director level or above. The Board of Directors currently comprises one woman and seven men. The Board of Directorsâ target is to include at least two female board members by the end of 2021, which we intend to achieve. However, during 2019 we believe the board composition was ideally suited to our current activities and have not made changes.</td></tr><tr><td colspan="1">Orphazyme values the personal development of its employees and offers employees the opportunity to participate in conferences and courses in order to strengthen their professional competences. Policies regarding staff matters are further elaborated in the Employee Handbook.</td></tr></table></mrv:StatementOfTargetFiguresAndPoliciesForTheUnderrepresentedGender>
<ifrs-full:ResearchAndDevelopmentExpense contextRef="ctx1" unitRef="vDKK" decimals="-3">285413000</ifrs-full:ResearchAndDevelopmentExpense>
<ifrs-full:AdministrativeExpense contextRef="ctx1" unitRef="vDKK" decimals="-3">50541000</ifrs-full:AdministrativeExpense>
<ifrs-full:ProfitLossFromOperatingActivities contextRef="ctx1" unitRef="vDKK" decimals="-3">-335954000</ifrs-full:ProfitLossFromOperatingActivities>
<ifrs-full:FinanceIncome contextRef="ctx1" unitRef="vDKK" decimals="-3">316000</ifrs-full:FinanceIncome>
<ifrs-full:FinanceCosts contextRef="ctx1" unitRef="vDKK" decimals="-3">7359000</ifrs-full:FinanceCosts>
<ifrs-full:ProfitLossBeforeTax contextRef="ctx1" unitRef="vDKK" decimals="-3">-342997000</ifrs-full:ProfitLossBeforeTax>
<ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="ctx1" unitRef="vDKK" decimals="-3">-5500000</ifrs-full:IncomeTaxExpenseContinuingOperations>
<ifrs-full:ProfitLoss contextRef="ctx1" unitRef="vDKK" decimals="-3">-337497000</ifrs-full:ProfitLoss>
<ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax contextRef="ctx1" unitRef="vDKK" decimals="-3">67000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
<ifrs-full:ComprehensiveIncome contextRef="ctx1" unitRef="vDKK" decimals="-3">-337430000</ifrs-full:ComprehensiveIncome>
<ifrs-full:DilutedEarningsLossPerShare contextRef="ctx1" unitRef="share" decimals="4">-16.8700</ifrs-full:DilutedEarningsLossPerShare>
<ifrs-full:BasicEarningsLossPerShare contextRef="ctx1" unitRef="share" decimals="4">-16.8700</ifrs-full:BasicEarningsLossPerShare>
<ifrs-full:AdjustmentsForSharebasedPayments contextRef="ctx1" unitRef="vDKK" decimals="-3">2549000</ifrs-full:AdjustmentsForSharebasedPayments>
<ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="ctx1" unitRef="vDKK" decimals="-3">3803000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
<ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="ctx1" unitRef="vDKK" decimals="-3">0</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
<ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="ctx1" unitRef="vDKK" decimals="-3">-5500000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
<ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="ctx1" unitRef="vDKK" decimals="-3">-4793000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
<ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="ctx1" unitRef="vDKK" decimals="-3">-326818000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
<ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="ctx1" unitRef="vDKK" decimals="-3">508000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
<ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="ctx1" unitRef="vDKK" decimals="-3">2777000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
<ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="ctx1" unitRef="vDKK" decimals="-3">-3285000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
<ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="ctx1" unitRef="vDKK" decimals="-3">62758000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
<ifrs-full:PaymentsOfFinanceLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="ctx1" unitRef="vDKK" decimals="-3">3838000</ifrs-full:PaymentsOfFinanceLeaseLiabilitiesClassifiedAsFinancingActivities>
<ifrs-full:ProceedsFromIssuingShares contextRef="ctx1" unitRef="vDKK" decimals="-3">19000</ifrs-full:ProceedsFromIssuingShares>
<ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="ctx1" unitRef="vDKK" decimals="-3">58939000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
<ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="ctx1" unitRef="vDKK" decimals="-3">-271164000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
<ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="ctx1" unitRef="vDKK" decimals="-3">46000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
<sob:StatementByExecutiveAndSupervisoryBoards contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">STATEMENT BY THE BOARD OF DIRECTORS AND EXECUTIVE MANAGEMENT</td></tr></table></sob:StatementByExecutiveAndSupervisoryBoards>
<sob:IdentificationOfApprovedAnnualReport contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">The Board of Directors and Executive Management have today considered and approved the Annual Report of Orphazyme A/S for the financial year January 1-December 31, 2019.</td></tr></table></sob:IdentificationOfApprovedAnnualReport>
<sob:ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">The consolidated financial statements of the Group and the Parent Companyâs financial statements have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB) and in accordance with IFRS as endorsed by the EU as well as additional disclosure requirements under the Danish Financial Statements Act.</td></tr></table></sob:ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement>
<sob:ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">In our opinion, the Groupâs consolidated financial statements and the Parent Company financial statements provide a fair presentation of the assets, liabilities, and financial position at December 31, 2019 and of the results of the Groupâs and Parent Companyâs operations and cash flows for the financial year January 1âDecember 31, 2019.</td></tr></table></sob:ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults>
<sob:ManagementsStatementAboutManagementsReview contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">In our opinion, Managementâs Review provides a fair presentation of the development in the Groupâs operations and financial circumstances, the results of the year, and the overall financial position of the Group as well as a description of the most significant risks and elements of uncertainty facing the Group.</td></tr></table></sob:ManagementsStatementAboutManagementsReview>
<sob:RecommendationForApprovalOfAnnualReportByGeneralMeeting contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">We recommend that the Annual Report be adopted at the Annual General Meeting on March 26, 2020.</td></tr></table></sob:RecommendationForApprovalOfAnnualReportByGeneralMeeting>
<sob:PlaceOfSignatureOfStatement contextRef="ctx1" xml:lang="da">Copenhagen</sob:PlaceOfSignatureOfStatement>
<sob:DateOfApprovalOfAnnualReport contextRef="ctx1">2020-02-28</sob:DateOfApprovalOfAnnualReport>
<arr:IndependentAuditorsReportsAudit contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Independent auditors' report</td></tr></table></arr:IndependentAuditorsReportsAudit>
<arr:AddresseeOfAuditorsReportOnAuditedFinancialStatements contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">TO THE SHAREHOLDERS OF ORPHAZYME A/S</td></tr></table></arr:AddresseeOfAuditorsReportOnAuditedFinancialStatements>
<arr:OpinionOnAuditedFinancialStatements contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">OPINION</td></tr><tr><td colspan="1">We have audited the consolidated financial statements and the parent company financial statements of Orphazyme A/S for the financial year January 1 â December 31, 2019, which comprise statement of profit or loss and other comprehensive income, statement of financial position, statement of changes in shareholdersâ equity, statement of cash flow, and notes, including accounting policies, for the Group and the Parent Company. The consolidated financial statements and the parent company financial statements are prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB) and in accordance with IFRS as endorsed by the EU as well as additional disclosure requirements under the Danish Financial Statements Act.</td></tr><tr><td colspan="1">In our opinion, the consolidated financial statements and the parent company financial statements give a true and fair view of the financial position of the Group and the Parent Company at December 31, 2019 and of the results of the Groupâs and the Parent Companyâs operations and cash flows for the financial year January 1 â December 31, 2019 in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB) and in accordance with IFRS as endorsed by the EU as well as additional disclosure requirements under the Danish Financial Statements Act.</td></tr><tr><td colspan="1">Our opinion is consistent with our long-form audit report to the Audit Committee and the Board of Directors.</td></tr></table></arr:OpinionOnAuditedFinancialStatements>
<arr:DescriptionOfQualificationsOfAuditedFinancialStatements contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">BASIS FOR OPINION</td></tr><tr><td colspan="1">We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the âAuditorâs responsibilities for the audit of the consolidated financial statements and the parent company financial statementsâ (hereinafter collectively referred to as âthe financial statementsâ) section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.</td></tr><tr><td colspan="1">Independence</td></tr><tr><td colspan="1">We are independent of the Group in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these rules and requirements.</td></tr><tr><td colspan="1">To the best of our knowledge, we have not provided any prohibited non-audit services as described in article 5(1) of Regulation (EU) no. 537/2014.</td></tr><tr><td colspan="1">Appointment of auditor</td></tr><tr><td colspan="1">We were initially appointed as auditor of Orphazyme A/S on December 4, 2015 for the financial year July 1 to December 31, 2015. We have been reappointed annually by resolution of the general meeting for a total consecutive period of 5 years up until the financial year 2019.</td></tr></table></arr:DescriptionOfQualificationsOfAuditedFinancialStatements>
<arr:KeyAuditMattersAudit contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">KEY AUDIT MATTERS</td></tr><tr><td colspan="1">Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial statements for the financial year 2019. These matters were addressed during our audit of the financial statements as a whole and in forming our opinion thereon. We do not provide a separate opinion on these matters. For each matter below, our description of how our audit addressed the matter is provided in that context.</td></tr><tr><td colspan="1">We have fulfilled our responsibilities described in the âAuditorâs responsibilities for the audit of the financial statementsâ section, including in relation to the key audit matters below. Accordingly, our audit included the design and performance of procedures to respond to our assessment of the risks of material misstatement of the financial statements. The results of our audit procedures, including the procedures performed to address the matters below, provide the basis for our audit opinion on the financial statements.</td></tr></table><br><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Key audit matters</td></tr><tr><td colspan="1">Accrual for costs incurred through Clinical Research Organisations (CROs)</td></tr><tr><td colspan="1">Orphazyme has entered into several clinical research contracts with Clinical Research Organisations (CROs) that perform research and development for the Company.</td></tr><tr><td colspan="1">Due to the materiality of these arrangements and since they cover multiple periods, recognition of the transactions in the correct period requires Management to make significant estimates.</td></tr><tr><td colspan="1">We focused on this area due to materiality and because the arrangements and the related accounting treatment of accruals accounting for CRO costs require significant estimation by Management.</td></tr><tr><td colspan="1">Refer to Note 2.1, 3.4 and 3.5 to the Consolidated Financial Statements.</td></tr><tr><td colspan="1">Funding</td></tr><tr><td colspan="1">In line with the business plan Orphazyme incurred substantial net loss and net operating cash outflows in 2019 and is expected to continue so in 2020.</td></tr><tr><td colspan="1">Cash and financial assets are monitored on a regular basis by Management and the Board of Directors in assessing current and long-term capital needs.</td></tr><tr><td colspan="1">How our audit addressed the key audit matter</td></tr><tr><td colspan="1">We have evaluated relevant processes including Managementâs controls to ensure that CRO contracts are recognised and measured appropriately on an ongoing basis.</td></tr><tr><td colspan="1">We obtained Managementâs calculations for CRO accruals at year-end and reconciled inputs and key assumptions to underlying terms and conditions in the agreements and relevant internal and external sources â and assessed the accuracy of the accruals for CRO services received â including assessed the accuracy of the accruals in previous periods. Furthermore, the CRO accrual models have been tested for clerical accuracy.</td></tr><tr><td colspan="1">We assessed whether the disclosures in relation to CRO accruals were appropriate and met the requirements of the accounting standards.</td></tr><tr><td colspan="1">We have evaluated relevant processes, including Managementâs controls, supporting Managementâs and the Board of Directorsâ assessment of current and long-term capital needs, including forecasting models, budgeting procedures etc. Managementâs processes and controls have been designed to ensure that all available information about the future, which is at least, but is not limited to, twelve months from the end of the reporting period has been taken into account.</td></tr></table><br><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">Key audit matters</td></tr><tr><td colspan="1">Due to uncertainty as to the timing and extend of both cash outflows related to the operations, especially costs associated with clinical trials as well as proceeds from capital increases or other means of funding of Orphazyme, the assessment of capital needs requires management to make significant judgment.</td></tr><tr><td colspan="1">As at December 31, 2019, the Management and the Board of Directors assessed that addition funding was required in order to fund Orphazymeâs operations for the entire 12 months period ending December 31, 2020. Thus, on this basis, measures were taken and on February 7, 2020 Orphazyme completed an offering of 7,032,937 shares in a directed issue and private placement and raised approximately DKK 745 million (see Note 4.7)</td></tr><tr><td colspan="1">The Management and the Board of Directors assess that the net proceeds from the transaction is sufficient to cover Orphazymeâs financing needs until well into 2021.</td></tr><tr><td colspan="1">We focused on this area due to materiality and because the assessment of capital need requires significant judgment by Management.</td></tr><tr><td colspan="1">Refer to Note 4.1 and 4.7 to the Consolidated Financial Statements.</td></tr><tr><td colspan="1">How our audit addressed the key audit matter</td></tr><tr><td colspan="1">We obtained Managementâs financial forecasts for 2020 as approved by the Board of Directors at year-end and reconciled inputs and key assumptions to underlying business plans, trial models developed and similar, as well as other relevant internal and external sources â and assessed the companyâs ability to fund operations of Orphazyme for at least twelve months from December 31, 2019. In this context, we have also discussed measures taken by management and Board of Directors to secure additional funding to the company. We have tested post balance sheet events, including performed detailed testing of the completed offering of shares and the receipt of approximately DKK 745 million after the balance sheet date.</td></tr><tr><td colspan="1">We assessed whether the disclosures in relation to the companyâs capital management procedures and subsequent events disclosures were appropriate and met the requirements of the accounting standards.</td></tr></table></arr:KeyAuditMattersAudit>
<arr:StatementOnManagementsReviewAuditorsReportOnAuditedFinancialStatements contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">STATEMENT ON THE MANAGEMENTâS REVIEW</td></tr><tr><td colspan="1">Management is responsible for the Managementâs review.</td></tr><tr><td colspan="1">Our opinion on the financial statements does not cover the Managementâs review, and we do not express any form of assurance conclusion thereon.</td></tr><tr><td colspan="1">In connection with our audit of the financial statements, our responsibility is to read the Managementâs review and, in doing so, consider whether the Managementâs review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.</td></tr><tr><td colspan="1">Moreover, it is our responsibility to consider whether the Managementâs review provides the information required under the Danish Financial Statements Act.</td></tr><tr><td colspan="1">Based on the work we have performed, we conclude that the Managementâs review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of the Managementâs review.</td></tr></table></arr:StatementOnManagementsReviewAuditorsReportOnAuditedFinancialStatements>
<arr:StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatements contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">MANAGEMENTâS RESPONSIBILITIES FOR THE FINANCIAL STATEMENTS</td></tr><tr><td colspan="1">Management is responsible for the preparation of consolidated financial statements and parent company financial statements that give a true and fair view in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB) and in accordance with IFRS as endorsed by the EU as well as additional disclosure requirements under the Danish Financial Statements Act and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.</td></tr><tr><td colspan="1">In preparing the financial statements, Management is responsible for assessing the Groupâs and the Parent Companyâs ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Group or the Parent Company or to cease operations, or has no realistic alternative but to do so.</td></tr></table></arr:StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatements>
<arr:StatementOfAuditorsResponsibilityForAuditAndAuditPerformed contextRef="ctx1" xml:lang="da"><table xmlns="http://www.w3.org/1999/xhtml" style="border-right: 0px; border-top: 0px; border-left: 0px; width: 650px; border-bottom: 0px; border-collapse: collapse" width="100%"><tr><td colspan="1">AUDITORâS RESPONSIBILITIES FOR THE AUDIT OF THE FINANCIAL STATEMENTS</td></tr><tr><td colspan="1">Our objectives are to obtain reasonable assurance as to whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditorâs report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.</td></tr><tr><td colspan="1">As part of an audit conducted in accordance with ISAs and additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also</td></tr><tr><td colspan="1">â¢Â      Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control.</td></tr><tr><td colspan="1">â¢Â      Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Groupâs and the Parent Companyâs internal control.</td></tr><tr><td colspan="1">â¢Â      Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.</td></tr><tr><td colspan="1">â¢Â      Conclude on the appropriateness of Managementâs use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Groupâs and the Parent Companyâs ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditorâs report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditorâs report. However, future events or conditions may cause the Group and the Parent Company to cease to continue as a going concern.</td></tr><tr><td colspan="1">â¢Â     Evaluate the overall presentation, structure and contents of the financial statements, including the note disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.</td></tr><tr><td colspan="1">â¢Â     Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.</td></tr><tr><td colspan="1">We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.</td></tr><tr><td colspan="1">We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.</td></tr><tr><td colspan="1">From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements and the parent company financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditorâs report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.</td></tr></table></arr:StatementOfAuditorsResponsibilityForAuditAndAuditPerformed>
<arr:SignatureOfAuditorsDate contextRef="ctx1">2020-02-28</arr:SignatureOfAuditorsDate>
<arr:SignatureOfAuditorsPlace contextRef="ctx1" xml:lang="da">Copenhagen</arr:SignatureOfAuditorsPlace>
<gsd:InformationOnTypeOfSubmittedReport contextRef="ctx1">Ã
rsrapport</gsd:InformationOnTypeOfSubmittedReport>
<gsd:IdentificationNumberCvrOfSubmittingEnterprise contextRef="ctx1">33771231</gsd:IdentificationNumberCvrOfSubmittingEnterprise>
<gsd:NameOfSubmittingEnterprise contextRef="ctx1" xml:lang="da">PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab</gsd:NameOfSubmittingEnterprise>
<gsd:AddressOfSubmittingEnterpriseStreetAndNumber contextRef="ctx1" xml:lang="da">Strandvejen 44</gsd:AddressOfSubmittingEnterpriseStreetAndNumber>
<gsd:AddressOfSubmittingEnterprisePostcodeAndTown contextRef="ctx1" xml:lang="da">2900 Hellerup</gsd:AddressOfSubmittingEnterprisePostcodeAndTown>
<gsd:PrecedingReportingPeriodStartDate contextRef="ctx1">2018-01-01</gsd:PrecedingReportingPeriodStartDate>
<gsd:PredingReportingPeriodEndDate contextRef="ctx1">2018-12-31</gsd:PredingReportingPeriodEndDate>
<cmn:TypeOfAuditorAssistance contextRef="ctx1">Revisionspåtegning</cmn:TypeOfAuditorAssistance>
<ifrs-full:ResearchAndDevelopmentExpense contextRef="ctx2" unitRef="vDKK" decimals="-3">196525000</ifrs-full:ResearchAndDevelopmentExpense>
<ifrs-full:AdministrativeExpense contextRef="ctx2" unitRef="vDKK" decimals="-3">35127000</ifrs-full:AdministrativeExpense>
<ifrs-full:ProfitLossFromOperatingActivities contextRef="ctx2" unitRef="vDKK" decimals="-3">-231652000</ifrs-full:ProfitLossFromOperatingActivities>
<ifrs-full:FinanceIncome contextRef="ctx2" unitRef="vDKK" decimals="-3">5000</ifrs-full:FinanceIncome>
<ifrs-full:FinanceCosts contextRef="ctx2" unitRef="vDKK" decimals="-3">3453000</ifrs-full:FinanceCosts>
<ifrs-full:ProfitLossBeforeTax contextRef="ctx2" unitRef="vDKK" decimals="-3">-235100000</ifrs-full:ProfitLossBeforeTax>
<ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="ctx2" unitRef="vDKK" decimals="-3">-5500000</ifrs-full:IncomeTaxExpenseContinuingOperations>
<ifrs-full:ProfitLoss contextRef="ctx2" unitRef="vDKK" decimals="-3">-229600000</ifrs-full:ProfitLoss>
<ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax contextRef="ctx2" unitRef="vDKK" decimals="-3">42000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
<ifrs-full:ComprehensiveIncome contextRef="ctx2" unitRef="vDKK" decimals="-3">-229558000</ifrs-full:ComprehensiveIncome>
<ifrs-full:DilutedEarningsLossPerShare contextRef="ctx2" unitRef="share" decimals="4">-11.4900</ifrs-full:DilutedEarningsLossPerShare>
<ifrs-full:BasicEarningsLossPerShare contextRef="ctx2" unitRef="share" decimals="4">-11.4900</ifrs-full:BasicEarningsLossPerShare>
<ifrs-full:AdjustmentsForSharebasedPayments contextRef="ctx2" unitRef="vDKK" decimals="-3">2105000</ifrs-full:AdjustmentsForSharebasedPayments>
<ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="ctx2" unitRef="vDKK" decimals="-3">1366000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
<ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="ctx2" unitRef="vDKK" decimals="-3">-491000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
<ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="ctx2" unitRef="vDKK" decimals="-3">-5500000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
<ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="ctx2" unitRef="vDKK" decimals="-3">-2957000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
<ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="ctx2" unitRef="vDKK" decimals="-3">-234764000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
<ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="ctx2" unitRef="vDKK" decimals="-3">1603000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
<ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="ctx2" unitRef="vDKK" decimals="-3">743000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
<ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="ctx2" unitRef="vDKK" decimals="-3">-2346000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
<ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="ctx2" unitRef="vDKK" decimals="-3">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
<ifrs-full:PaymentsOfFinanceLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="ctx2" unitRef="vDKK" decimals="-3">0</ifrs-full:PaymentsOfFinanceLeaseLiabilitiesClassifiedAsFinancingActivities>
<ifrs-full:ProceedsFromIssuingShares contextRef="ctx2" unitRef="vDKK" decimals="-3">0</ifrs-full:ProceedsFromIssuingShares>
<ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="ctx2" unitRef="vDKK" decimals="-3">0</ifrs-full:CashFlowsFromUsedInFinancingActivities>
<ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="ctx2" unitRef="vDKK" decimals="-3">-237110000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
<ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="ctx2" unitRef="vDKK" decimals="-3">81000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
<ifrs-full:ResearchAndDevelopmentExpense contextRef="ctx3" unitRef="vDKK" decimals="-3">285413000</ifrs-full:ResearchAndDevelopmentExpense>
<ifrs-full:AdministrativeExpense contextRef="ctx3" unitRef="vDKK" decimals="-3">49682000</ifrs-full:AdministrativeExpense>
<ifrs-full:ProfitLossFromOperatingActivities contextRef="ctx3" unitRef="vDKK" decimals="-3">-335095000</ifrs-full:ProfitLossFromOperatingActivities>
<ifrs-full:FinanceIncome contextRef="ctx3" unitRef="vDKK" decimals="-3">316000</ifrs-full:FinanceIncome>
<ifrs-full:FinanceCosts contextRef="ctx3" unitRef="vDKK" decimals="-3">7359000</ifrs-full:FinanceCosts>
<ifrs-full:ProfitLossBeforeTax contextRef="ctx3" unitRef="vDKK" decimals="-3">-342138000</ifrs-full:ProfitLossBeforeTax>
<ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="ctx3" unitRef="vDKK" decimals="-3">-5500000</ifrs-full:IncomeTaxExpenseContinuingOperations>
<ifrs-full:ProfitLoss contextRef="ctx3" unitRef="vDKK" decimals="-3">-336638000</ifrs-full:ProfitLoss>
<ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax contextRef="ctx3" unitRef="vDKK" decimals="-3">0</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
<ifrs-full:ComprehensiveIncome contextRef="ctx3" unitRef="vDKK" decimals="-3">-336638000</ifrs-full:ComprehensiveIncome>
<ifrs-full:DilutedEarningsLossPerShare contextRef="ctx3" unitRef="share" decimals="4">-16.3500</ifrs-full:DilutedEarningsLossPerShare>
<ifrs-full:BasicEarningsLossPerShare contextRef="ctx3" unitRef="share" decimals="4">-16.3500</ifrs-full:BasicEarningsLossPerShare>
<ifrs-full:AdjustmentsForSharebasedPayments contextRef="ctx3" unitRef="vDKK" decimals="-3">2550000</ifrs-full:AdjustmentsForSharebasedPayments>
<ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="ctx3" unitRef="vDKK" decimals="-3">5010000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
<ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="ctx3" unitRef="vDKK" decimals="-3">0</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
<ifrs-dk:AdjustmentsForDecreaseIncreaseInPayablesFromGroupEnterprises contextRef="ctx3" unitRef="vDKK" decimals="-3">825000</ifrs-dk:AdjustmentsForDecreaseIncreaseInPayablesFromGroupEnterprises>
<ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="ctx3" unitRef="vDKK" decimals="-3">-5500000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
<ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="ctx3" unitRef="vDKK" decimals="-3">-4793000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
<ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="ctx3" unitRef="vDKK" decimals="-3">-325504000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
<ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="ctx3" unitRef="vDKK" decimals="-3">508000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
<ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="ctx3" unitRef="vDKK" decimals="-3">2777000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
<ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="ctx3" unitRef="vDKK" decimals="-3">-3285000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
<ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="ctx3" unitRef="vDKK" decimals="-3">62758000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
<ifrs-full:PaymentsOfFinanceLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="ctx3" unitRef="vDKK" decimals="-3">3838000</ifrs-full:PaymentsOfFinanceLeaseLiabilitiesClassifiedAsFinancingActivities>
<ifrs-full:ProceedsFromIssuingShares contextRef="ctx3" unitRef="vDKK" decimals="-3">19000</ifrs-full:ProceedsFromIssuingShares>
<ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="ctx3" unitRef="vDKK" decimals="-3">58939000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
<ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="ctx3" unitRef="vDKK" decimals="-3">-269850000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
<ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="ctx3" unitRef="vDKK" decimals="-3">-23000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
<ifrs-full:ResearchAndDevelopmentExpense contextRef="ctx4" unitRef="vDKK" decimals="-3">196525000</ifrs-full:ResearchAndDevelopmentExpense>
<ifrs-full:AdministrativeExpense contextRef="ctx4" unitRef="vDKK" decimals="-3">35127000</ifrs-full:AdministrativeExpense>
<ifrs-full:ProfitLossFromOperatingActivities contextRef="ctx4" unitRef="vDKK" decimals="-3">-231652000</ifrs-full:ProfitLossFromOperatingActivities>
<ifrs-full:FinanceIncome contextRef="ctx4" unitRef="vDKK" decimals="-3">5000</ifrs-full:FinanceIncome>
<ifrs-full:FinanceCosts contextRef="ctx4" unitRef="vDKK" decimals="-3">3453000</ifrs-full:FinanceCosts>
<ifrs-full:ProfitLossBeforeTax contextRef="ctx4" unitRef="vDKK" decimals="-3">-235100000</ifrs-full:ProfitLossBeforeTax>
<ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="ctx4" unitRef="vDKK" decimals="-3">-5500000</ifrs-full:IncomeTaxExpenseContinuingOperations>
<ifrs-full:ProfitLoss contextRef="ctx4" unitRef="vDKK" decimals="-3">-229600000</ifrs-full:ProfitLoss>
<ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax contextRef="ctx4" unitRef="vDKK" decimals="-3">-51000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationNetOfTax>
<ifrs-full:ComprehensiveIncome contextRef="ctx4" unitRef="vDKK" decimals="-3">-229651000</ifrs-full:ComprehensiveIncome>
<ifrs-full:DilutedEarningsLossPerShare contextRef="ctx4" unitRef="share" decimals="4">-11.4900</ifrs-full:DilutedEarningsLossPerShare>
<ifrs-full:BasicEarningsLossPerShare contextRef="ctx4" unitRef="share" decimals="4">-11.4900</ifrs-full:BasicEarningsLossPerShare>
<ifrs-full:AdjustmentsForSharebasedPayments contextRef="ctx4" unitRef="vDKK" decimals="-3">2105000</ifrs-full:AdjustmentsForSharebasedPayments>
<ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="ctx4" unitRef="vDKK" decimals="-3">1366000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
<ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="ctx4" unitRef="vDKK" decimals="-3">-491000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
<ifrs-dk:AdjustmentsForDecreaseIncreaseInPayablesFromGroupEnterprises contextRef="ctx4" unitRef="vDKK" decimals="-3">-825000</ifrs-dk:AdjustmentsForDecreaseIncreaseInPayablesFromGroupEnterprises>
<ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="ctx4" unitRef="vDKK" decimals="-3">-5500000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
<ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="ctx4" unitRef="vDKK" decimals="-3">-2957000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
<ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="ctx4" unitRef="vDKK" decimals="-3">-235009000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
<ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="ctx4" unitRef="vDKK" decimals="-3">1603000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
<ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="ctx4" unitRef="vDKK" decimals="-3">743000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
<ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="ctx4" unitRef="vDKK" decimals="-3">-3553000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
<ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="ctx4" unitRef="vDKK" decimals="-3">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
<ifrs-full:PaymentsOfFinanceLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="ctx4" unitRef="vDKK" decimals="-3">0</ifrs-full:PaymentsOfFinanceLeaseLiabilitiesClassifiedAsFinancingActivities>
<ifrs-full:ProceedsFromIssuingShares contextRef="ctx4" unitRef="vDKK" decimals="-3">0</ifrs-full:ProceedsFromIssuingShares>
<ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="ctx4" unitRef="vDKK" decimals="-3">0</ifrs-full:CashFlowsFromUsedInFinancingActivities>
<ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="ctx4" unitRef="vDKK" decimals="-3">-238562000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
<ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="ctx4" unitRef="vDKK" decimals="-3">-50000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
<ifrs-dk:Licenses contextRef="ctx5" unitRef="vDKK" decimals="-3">10539000</ifrs-dk:Licenses>
<ifrs-dk:RightofuseAssets contextRef="ctx5" unitRef="vDKK" decimals="-3">13903000</ifrs-dk:RightofuseAssets>
<ifrs-full:PropertyPlantAndEquipment contextRef="ctx5" unitRef="vDKK" decimals="-3">3685000</ifrs-full:PropertyPlantAndEquipment>
<ifrs-full:CurrentTaxAssetsNoncurrent contextRef="ctx5" unitRef="vDKK" decimals="-3">2750000</ifrs-full:CurrentTaxAssetsNoncurrent>
<ifrs-dk:NoncurrentPrepaymentsDeposits contextRef="ctx5" unitRef="vDKK" decimals="-3">1652000</ifrs-dk:NoncurrentPrepaymentsDeposits>
<ifrs-full:NoncurrentAssets contextRef="ctx5" unitRef="vDKK" decimals="-3">32529000</ifrs-full:NoncurrentAssets>
<ifrs-full:CurrentTaxAssetsCurrent contextRef="ctx5" unitRef="vDKK" decimals="-3">5500000</ifrs-full:CurrentTaxAssetsCurrent>
<ifrs-full:TradeAndOtherCurrentReceivables contextRef="ctx5" unitRef="vDKK" decimals="-3">19137000</ifrs-full:TradeAndOtherCurrentReceivables>
<ifrs-full:Cash contextRef="ctx5" unitRef="vDKK" decimals="-3">123588000</ifrs-full:Cash>
<ifrs-full:CurrentAssets contextRef="ctx5" unitRef="vDKK" decimals="-3">148225000</ifrs-full:CurrentAssets>
<ifrs-full:Assets contextRef="ctx5" unitRef="vDKK" decimals="-3">180754000</ifrs-full:Assets>
<ifrs-full:IssuedCapital contextRef="ctx5" unitRef="vDKK" decimals="-3">19984000</ifrs-full:IssuedCapital>
<ifrs-full:SharePremium contextRef="ctx5" unitRef="vDKK" decimals="-3">924021000</ifrs-full:SharePremium>
<ifrs-full:OtherReserves contextRef="ctx5" unitRef="vDKK" decimals="-3">7982000</ifrs-full:OtherReserves>
<ifrs-full:RetainedEarnings contextRef="ctx5" unitRef="vDKK" decimals="-3">-899018000</ifrs-full:RetainedEarnings>
<ifrs-full:Equity contextRef="ctx5" unitRef="vDKK" decimals="-3">52969000</ifrs-full:Equity>
<ifrs-full:LongtermBorrowings contextRef="ctx5" unitRef="vDKK" decimals="-3">51606000</ifrs-full:LongtermBorrowings>
<ifrs-full:NoncurrentFinanceLeaseLiabilities contextRef="ctx5" unitRef="vDKK" decimals="-3">9813000</ifrs-full:NoncurrentFinanceLeaseLiabilities>
<ifrs-full:OtherNoncurrentLiabilities contextRef="ctx5" unitRef="vDKK" decimals="-3">378000</ifrs-full:OtherNoncurrentLiabilities>
<ifrs-full:NoncurrentLiabilities contextRef="ctx5" unitRef="vDKK" decimals="-3">61797000</ifrs-full:NoncurrentLiabilities>
<ifrs-full:ShorttermBorrowings contextRef="ctx5" unitRef="vDKK" decimals="-3">12813000</ifrs-full:ShorttermBorrowings>
<ifrs-full:TradeAndOtherCurrentPayables contextRef="ctx5" unitRef="vDKK" decimals="-3">32390000</ifrs-full:TradeAndOtherCurrentPayables>
<ifrs-full:OtherCurrentLiabilities contextRef="ctx5" unitRef="vDKK" decimals="-3">20785000</ifrs-full:OtherCurrentLiabilities>
<ifrs-full:CurrentLiabilities contextRef="ctx5" unitRef="vDKK" decimals="-3">65988000</ifrs-full:CurrentLiabilities>
<ifrs-full:EquityAndLiabilities contextRef="ctx5" unitRef="vDKK" decimals="-3">180754000</ifrs-full:EquityAndLiabilities>
<ifrs-full:CashAndCashEquivalents contextRef="ctx5" unitRef="vDKK" decimals="-3">123588000</ifrs-full:CashAndCashEquivalents>
<ifrs-dk:Licenses contextRef="ctx6" unitRef="vDKK" decimals="-3">10744000</ifrs-dk:Licenses>
<ifrs-dk:RightofuseAssets contextRef="ctx6" unitRef="vDKK" decimals="-3">0</ifrs-dk:RightofuseAssets>
<ifrs-full:PropertyPlantAndEquipment contextRef="ctx6" unitRef="vDKK" decimals="-3">1940000</ifrs-full:PropertyPlantAndEquipment>
<ifrs-full:CurrentTaxAssetsNoncurrent contextRef="ctx6" unitRef="vDKK" decimals="-3">2750000</ifrs-full:CurrentTaxAssetsNoncurrent>
<ifrs-dk:NoncurrentPrepaymentsDeposits contextRef="ctx6" unitRef="vDKK" decimals="-3">2531000</ifrs-dk:NoncurrentPrepaymentsDeposits>
<ifrs-full:NoncurrentAssets contextRef="ctx6" unitRef="vDKK" decimals="-3">17965000</ifrs-full:NoncurrentAssets>
<ifrs-full:CurrentTaxAssetsCurrent contextRef="ctx6" unitRef="vDKK" decimals="-3">5500000</ifrs-full:CurrentTaxAssetsCurrent>
<ifrs-full:TradeAndOtherCurrentReceivables contextRef="ctx6" unitRef="vDKK" decimals="-3">23178000</ifrs-full:TradeAndOtherCurrentReceivables>
<ifrs-full:Cash contextRef="ctx6" unitRef="vDKK" decimals="-3">394706000</ifrs-full:Cash>
<ifrs-full:CurrentAssets contextRef="ctx6" unitRef="vDKK" decimals="-3">423384000</ifrs-full:CurrentAssets>
<ifrs-full:Assets contextRef="ctx6" unitRef="vDKK" decimals="-3">441349000</ifrs-full:Assets>
<ifrs-full:IssuedCapital contextRef="ctx6" unitRef="vDKK" decimals="-3">19939000</ifrs-full:IssuedCapital>
<ifrs-full:SharePremium contextRef="ctx6" unitRef="vDKK" decimals="-3">924021000</ifrs-full:SharePremium>
<ifrs-full:OtherReserves contextRef="ctx6" unitRef="vDKK" decimals="-3">9112000</ifrs-full:OtherReserves>
<ifrs-full:RetainedEarnings contextRef="ctx6" unitRef="vDKK" decimals="-3">-564823000</ifrs-full:RetainedEarnings>
<ifrs-full:Equity contextRef="ctx6" unitRef="vDKK" decimals="-3">388249000</ifrs-full:Equity>
<ifrs-full:LongtermBorrowings contextRef="ctx6" unitRef="vDKK" decimals="-3">0</ifrs-full:LongtermBorrowings>
<ifrs-full:NoncurrentFinanceLeaseLiabilities contextRef="ctx6" unitRef="vDKK" decimals="-3">0</ifrs-full:NoncurrentFinanceLeaseLiabilities>
<ifrs-full:OtherNoncurrentLiabilities contextRef="ctx6" unitRef="vDKK" decimals="-3">105000</ifrs-full:OtherNoncurrentLiabilities>
<ifrs-full:NoncurrentLiabilities contextRef="ctx6" unitRef="vDKK" decimals="-3">105000</ifrs-full:NoncurrentLiabilities>
<ifrs-full:ShorttermBorrowings contextRef="ctx6" unitRef="vDKK" decimals="-3">0</ifrs-full:ShorttermBorrowings>
<ifrs-full:TradeAndOtherCurrentPayables contextRef="ctx6" unitRef="vDKK" decimals="-3">42183000</ifrs-full:TradeAndOtherCurrentPayables>
<ifrs-full:OtherCurrentLiabilities contextRef="ctx6" unitRef="vDKK" decimals="-3">10812000</ifrs-full:OtherCurrentLiabilities>
<ifrs-full:CurrentLiabilities contextRef="ctx6" unitRef="vDKK" decimals="-3">52995000</ifrs-full:CurrentLiabilities>
<ifrs-full:EquityAndLiabilities contextRef="ctx6" unitRef="vDKK" decimals="-3">441349000</ifrs-full:EquityAndLiabilities>
<ifrs-full:CashAndCashEquivalents contextRef="ctx6" unitRef="vDKK" decimals="-3">394706000</ifrs-full:CashAndCashEquivalents>
<ifrs-dk:Licenses contextRef="ctx7" unitRef="vDKK" decimals="-3">10539000</ifrs-dk:Licenses>
<ifrs-dk:RightofuseAssets contextRef="ctx7" unitRef="vDKK" decimals="-3">13903000</ifrs-dk:RightofuseAssets>
<ifrs-full:PropertyPlantAndEquipment contextRef="ctx7" unitRef="vDKK" decimals="-3">3685000</ifrs-full:PropertyPlantAndEquipment>
<ifrs-full:CurrentTaxAssetsNoncurrent contextRef="ctx7" unitRef="vDKK" decimals="-3">2750000</ifrs-full:CurrentTaxAssetsNoncurrent>
<ifrs-dk:NoncurrentPrepaymentsDeposits contextRef="ctx7" unitRef="vDKK" decimals="-3">1652000</ifrs-dk:NoncurrentPrepaymentsDeposits>
<ifrs-full:InvestmentsInSubsidiaries contextRef="ctx7" unitRef="vDKK" decimals="-3">0</ifrs-full:InvestmentsInSubsidiaries>
<ifrs-full:NoncurrentAssets contextRef="ctx7" unitRef="vDKK" decimals="-3">32529000</ifrs-full:NoncurrentAssets>
<ifrs-full:CurrentTaxAssetsCurrent contextRef="ctx7" unitRef="vDKK" decimals="-3">5500000</ifrs-full:CurrentTaxAssetsCurrent>
<ifrs-full:TradeAndOtherCurrentReceivables contextRef="ctx7" unitRef="vDKK" decimals="-3">18957000</ifrs-full:TradeAndOtherCurrentReceivables>
<ifrs-full:Cash contextRef="ctx7" unitRef="vDKK" decimals="-3">123251000</ifrs-full:Cash>
<ifrs-full:CurrentAssets contextRef="ctx7" unitRef="vDKK" decimals="-3">147708000</ifrs-full:CurrentAssets>
<ifrs-full:Assets contextRef="ctx7" unitRef="vDKK" decimals="-3">180237000</ifrs-full:Assets>
<ifrs-full:IssuedCapital contextRef="ctx7" unitRef="vDKK" decimals="-3">19984000</ifrs-full:IssuedCapital>
<ifrs-full:SharePremium contextRef="ctx7" unitRef="vDKK" decimals="-3">924021000</ifrs-full:SharePremium>
<ifrs-full:OtherReserves contextRef="ctx7" unitRef="vDKK" decimals="-3">7822000</ifrs-full:OtherReserves>
<ifrs-full:RetainedEarnings contextRef="ctx7" unitRef="vDKK" decimals="-3">-898159000</ifrs-full:RetainedEarnings>
<ifrs-full:Equity contextRef="ctx7" unitRef="vDKK" decimals="-3">53668000</ifrs-full:Equity>
<ifrs-full:LongtermBorrowings contextRef="ctx7" unitRef="vDKK" decimals="-3">51611000</ifrs-full:LongtermBorrowings>
<ifrs-full:NoncurrentFinanceLeaseLiabilities contextRef="ctx7" unitRef="vDKK" decimals="-3">9813000</ifrs-full:NoncurrentFinanceLeaseLiabilities>
<ifrs-full:OtherNoncurrentLiabilities contextRef="ctx7" unitRef="vDKK" decimals="-3">378000</ifrs-full:OtherNoncurrentLiabilities>
<ifrs-full:NoncurrentLiabilities contextRef="ctx7" unitRef="vDKK" decimals="-3">61802000</ifrs-full:NoncurrentLiabilities>
<ifrs-full:ShorttermBorrowings contextRef="ctx7" unitRef="vDKK" decimals="-3">12808000</ifrs-full:ShorttermBorrowings>
<ifrs-full:TradeAndOtherCurrentPayables contextRef="ctx7" unitRef="vDKK" decimals="-3">31173000</ifrs-full:TradeAndOtherCurrentPayables>
<ifrs-full:OtherCurrentLiabilities contextRef="ctx7" unitRef="vDKK" decimals="-3">20785000</ifrs-full:OtherCurrentLiabilities>
<ifrs-full:CurrentLiabilities contextRef="ctx7" unitRef="vDKK" decimals="-3">64766000</ifrs-full:CurrentLiabilities>
<ifrs-full:EquityAndLiabilities contextRef="ctx7" unitRef="vDKK" decimals="-3">180237000</ifrs-full:EquityAndLiabilities>
<ifrs-full:CashAndCashEquivalents contextRef="ctx7" unitRef="vDKK" decimals="-3">123250000</ifrs-full:CashAndCashEquivalents>
<ifrs-dk:Licenses contextRef="ctx8" unitRef="vDKK" decimals="-3">10744000</ifrs-dk:Licenses>
<ifrs-dk:RightofuseAssets contextRef="ctx8" unitRef="vDKK" decimals="-3">0</ifrs-dk:RightofuseAssets>
<ifrs-full:PropertyPlantAndEquipment contextRef="ctx8" unitRef="vDKK" decimals="-3">1940000</ifrs-full:PropertyPlantAndEquipment>
<ifrs-full:CurrentTaxAssetsNoncurrent contextRef="ctx8" unitRef="vDKK" decimals="-3">2750000</ifrs-full:CurrentTaxAssetsNoncurrent>
<ifrs-dk:NoncurrentPrepaymentsDeposits contextRef="ctx8" unitRef="vDKK" decimals="-3">2531000</ifrs-dk:NoncurrentPrepaymentsDeposits>
<ifrs-full:InvestmentsInSubsidiaries contextRef="ctx8" unitRef="vDKK" decimals="-3">1207000</ifrs-full:InvestmentsInSubsidiaries>
<ifrs-full:NoncurrentAssets contextRef="ctx8" unitRef="vDKK" decimals="-3">19172000</ifrs-full:NoncurrentAssets>
<ifrs-full:CurrentTaxAssetsCurrent contextRef="ctx8" unitRef="vDKK" decimals="-3">5500000</ifrs-full:CurrentTaxAssetsCurrent>
<ifrs-full:TradeAndOtherCurrentReceivables contextRef="ctx8" unitRef="vDKK" decimals="-3">23081000</ifrs-full:TradeAndOtherCurrentReceivables>
<ifrs-full:Cash contextRef="ctx8" unitRef="vDKK" decimals="-3">393123000</ifrs-full:Cash>
<ifrs-full:CurrentAssets contextRef="ctx8" unitRef="vDKK" decimals="-3">421704000</ifrs-full:CurrentAssets>
<ifrs-full:Assets contextRef="ctx8" unitRef="vDKK" decimals="-3">440876000</ifrs-full:Assets>
<ifrs-full:IssuedCapital contextRef="ctx8" unitRef="vDKK" decimals="-3">19939000</ifrs-full:IssuedCapital>
<ifrs-full:SharePremium contextRef="ctx8" unitRef="vDKK" decimals="-3">924021000</ifrs-full:SharePremium>
<ifrs-full:OtherReserves contextRef="ctx8" unitRef="vDKK" decimals="-3">9019000</ifrs-full:OtherReserves>
<ifrs-full:RetainedEarnings contextRef="ctx8" unitRef="vDKK" decimals="-3">-564823000</ifrs-full:RetainedEarnings>
<ifrs-full:Equity contextRef="ctx8" unitRef="vDKK" decimals="-3">388156000</ifrs-full:Equity>
<ifrs-full:LongtermBorrowings contextRef="ctx8" unitRef="vDKK" decimals="-3">826000</ifrs-full:LongtermBorrowings>
<ifrs-full:NoncurrentFinanceLeaseLiabilities contextRef="ctx8" unitRef="vDKK" decimals="-3">0</ifrs-full:NoncurrentFinanceLeaseLiabilities>
<ifrs-full:OtherNoncurrentLiabilities contextRef="ctx8" unitRef="vDKK" decimals="-3">105000</ifrs-full:OtherNoncurrentLiabilities>
<ifrs-full:NoncurrentLiabilities contextRef="ctx8" unitRef="vDKK" decimals="-3">931000</ifrs-full:NoncurrentLiabilities>
<ifrs-full:ShorttermBorrowings contextRef="ctx8" unitRef="vDKK" decimals="-3">0</ifrs-full:ShorttermBorrowings>
<ifrs-full:TradeAndOtherCurrentPayables contextRef="ctx8" unitRef="vDKK" decimals="-3">40977000</ifrs-full:TradeAndOtherCurrentPayables>
<ifrs-full:OtherCurrentLiabilities contextRef="ctx8" unitRef="vDKK" decimals="-3">10812000</ifrs-full:OtherCurrentLiabilities>
<ifrs-full:CurrentLiabilities contextRef="ctx8" unitRef="vDKK" decimals="-3">51789000</ifrs-full:CurrentLiabilities>
<ifrs-full:EquityAndLiabilities contextRef="ctx8" unitRef="vDKK" decimals="-3">440876000</ifrs-full:EquityAndLiabilities>
<ifrs-full:CashAndCashEquivalents contextRef="ctx8" unitRef="vDKK" decimals="-3">393123000</ifrs-full:CashAndCashEquivalents>
<ifrs-dk:NameOfComponentOfCashFlowsFromUsedInOperatingActivities contextRef="ctx9" xml:lang="da">Operating loss</ifrs-dk:NameOfComponentOfCashFlowsFromUsedInOperatingActivities>
<ifrs-dk:AmountOfComponentOfCashFlowsFromUsedInOperatingActivities contextRef="ctx9" unitRef="vDKK" decimals="-3">-335954000</ifrs-dk:AmountOfComponentOfCashFlowsFromUsedInOperatingActivities>
<ifrs-dk:NameOfComponentOfCashFlowsFromUsedInOperatingActivities contextRef="ctx10" xml:lang="da">Operating loss</ifrs-dk:NameOfComponentOfCashFlowsFromUsedInOperatingActivities>
<ifrs-dk:AmountOfComponentOfCashFlowsFromUsedInOperatingActivities contextRef="ctx10" unitRef="vDKK" decimals="-3">-231652000</ifrs-dk:AmountOfComponentOfCashFlowsFromUsedInOperatingActivities>
<ifrs-dk:NameOfComponentOfCashFlowsFromUsedInOperatingActivities contextRef="ctx11" xml:lang="da">Operating loss</ifrs-dk:NameOfComponentOfCashFlowsFromUsedInOperatingActivities>
<ifrs-dk:AmountOfComponentOfCashFlowsFromUsedInOperatingActivities contextRef="ctx11" unitRef="vDKK" decimals="-3">-335095000</ifrs-dk:AmountOfComponentOfCashFlowsFromUsedInOperatingActivities>
<ifrs-dk:NameOfComponentOfCashFlowsFromUsedInOperatingActivities contextRef="ctx12" xml:lang="da">Operating loss</ifrs-dk:NameOfComponentOfCashFlowsFromUsedInOperatingActivities>
<ifrs-dk:AmountOfComponentOfCashFlowsFromUsedInOperatingActivities contextRef="ctx12" unitRef="vDKK" decimals="-3">-231652000</ifrs-dk:AmountOfComponentOfCashFlowsFromUsedInOperatingActivities>
<ifrs-dk:NameOfComponentOfCashFlowsFromUsedInOperatingActivities contextRef="ctx13" xml:lang="da">Change in prepayments, deposits, and other receivables</ifrs-dk:NameOfComponentOfCashFlowsFromUsedInOperatingActivities>
<ifrs-dk:AmountOfComponentOfCashFlowsFromUsedInOperatingActivities contextRef="ctx13" unitRef="vDKK" decimals="-3">4920000</ifrs-dk:AmountOfComponentOfCashFlowsFromUsedInOperatingActivities>
<ifrs-dk:NameOfComponentOfCashFlowsFromUsedInOperatingActivities contextRef="ctx14" xml:lang="da">Change in prepayments, deposits, and other receivables</ifrs-dk:NameOfComponentOfCashFlowsFromUsedInOperatingActivities>
<ifrs-dk:AmountOfComponentOfCashFlowsFromUsedInOperatingActivities contextRef="ctx14" unitRef="vDKK" decimals="-3">-14578000</ifrs-dk:AmountOfComponentOfCashFlowsFromUsedInOperatingActivities>
<ifrs-dk:NameOfComponentOfCashFlowsFromUsedInOperatingActivities contextRef="ctx15" xml:lang="da">Change in prepayments, deposits, and other receivables</ifrs-dk:NameOfComponentOfCashFlowsFromUsedInOperatingActivities>
<ifrs-dk:AmountOfComponentOfCashFlowsFromUsedInOperatingActivities contextRef="ctx15" unitRef="vDKK" decimals="-3">5003000</ifrs-dk:AmountOfComponentOfCashFlowsFromUsedInOperatingActivities>
<ifrs-dk:NameOfComponentOfCashFlowsFromUsedInOperatingActivities contextRef="ctx16" xml:lang="da">Change in prepayments, deposits, and other receivables</ifrs-dk:NameOfComponentOfCashFlowsFromUsedInOperatingActivities>
<ifrs-dk:AmountOfComponentOfCashFlowsFromUsedInOperatingActivities contextRef="ctx16" unitRef="vDKK" decimals="-3">-14484000</ifrs-dk:AmountOfComponentOfCashFlowsFromUsedInOperatingActivities>
<ifrs-dk:NameOfComponentOfCashFlowsFromUsedInOperatingActivities contextRef="ctx17" xml:lang="da">Change in trade payables, Accruals, and other liabilities</ifrs-dk:NameOfComponentOfCashFlowsFromUsedInOperatingActivities>
<ifrs-dk:AmountOfComponentOfCashFlowsFromUsedInOperatingActivities contextRef="ctx17" unitRef="vDKK" decimals="-3">-2844000</ifrs-dk:AmountOfComponentOfCashFlowsFromUsedInOperatingActivities>
<ifrs-dk:NameOfComponentOfCashFlowsFromUsedInOperatingActivities contextRef="ctx18" xml:lang="da">Change in trade payables, Accruals, and other liabilities</ifrs-dk:NameOfComponentOfCashFlowsFromUsedInOperatingActivities>
<ifrs-dk:AmountOfComponentOfCashFlowsFromUsedInOperatingActivities contextRef="ctx18" unitRef="vDKK" decimals="-3">5943000</ifrs-dk:AmountOfComponentOfCashFlowsFromUsedInOperatingActivities>
<ifrs-dk:NameOfComponentOfCashFlowsFromUsedInOperatingActivities contextRef="ctx19" xml:lang="da">Change in trade payables, Accruals, and other liabilities</ifrs-dk:NameOfComponentOfCashFlowsFromUsedInOperatingActivities>
<ifrs-dk:AmountOfComponentOfCashFlowsFromUsedInOperatingActivities contextRef="ctx19" unitRef="vDKK" decimals="-3">-2854000</ifrs-dk:AmountOfComponentOfCashFlowsFromUsedInOperatingActivities>
<ifrs-dk:NameOfComponentOfCashFlowsFromUsedInOperatingActivities contextRef="ctx20" xml:lang="da">Change in trade payables, Accruals, and other liabilities</ifrs-dk:NameOfComponentOfCashFlowsFromUsedInOperatingActivities>
<ifrs-dk:AmountOfComponentOfCashFlowsFromUsedInOperatingActivities contextRef="ctx20" unitRef="vDKK" decimals="-3">4779000</ifrs-dk:AmountOfComponentOfCashFlowsFromUsedInOperatingActivities>
<ifrs-dk:NameOfComponentOfCashFlowsFromUsedInInvestingActivities contextRef="ctx21" xml:lang="da">Capital increase in subsidiaries</ifrs-dk:NameOfComponentOfCashFlowsFromUsedInInvestingActivities>
<ifrs-dk:AmountOfComponentOfCashFlowsFromUsedInInvestingActivities contextRef="ctx21" unitRef="vDKK" decimals="-3">0</ifrs-dk:AmountOfComponentOfCashFlowsFromUsedInInvestingActivities>
<ifrs-dk:NameOfComponentOfCashFlowsFromUsedInInvestingActivities contextRef="ctx22" xml:lang="da">Capital increase in subsidiaries</ifrs-dk:NameOfComponentOfCashFlowsFromUsedInInvestingActivities>
<ifrs-dk:AmountOfComponentOfCashFlowsFromUsedInInvestingActivities contextRef="ctx22" unitRef="vDKK" decimals="-3">-1207000</ifrs-dk:AmountOfComponentOfCashFlowsFromUsedInInvestingActivities>
<ifrs-full:CashAndCashEquivalents contextRef="ctx23" unitRef="vDKK" decimals="-3">394706000</ifrs-full:CashAndCashEquivalents>
<ifrs-full:CashAndCashEquivalents contextRef="ctx24" unitRef="vDKK" decimals="-3">631735000</ifrs-full:CashAndCashEquivalents>
<ifrs-full:CashAndCashEquivalents contextRef="ctx25" unitRef="vDKK" decimals="-3">393123000</ifrs-full:CashAndCashEquivalents>
<ifrs-full:CashAndCashEquivalents contextRef="ctx26" unitRef="vDKK" decimals="-3">631735000</ifrs-full:CashAndCashEquivalents>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx27" xml:lang="da">Georges Gemayel</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<cmn:TitleOfMemberOfSupervisoryBoard contextRef="ctx27" xml:lang="da">Chairman of the Board</cmn:TitleOfMemberOfSupervisoryBoard>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx28" xml:lang="da">Bo Jesper Hansen</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<cmn:TitleOfMemberOfSupervisoryBoard contextRef="ctx28" xml:lang="da">Deputy Chairman of the Board</cmn:TitleOfMemberOfSupervisoryBoard>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx29" xml:lang="da">Martin Bonde</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx30" xml:lang="da">Anders Hedegaard</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx31" xml:lang="da">Rémi Droller</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx32" xml:lang="da">Martijn Kleijwegt</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx33" xml:lang="da">Sten Verland</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx34" xml:lang="da">Catherine Moukheibir</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<cmn:NameAndSurnameOfMemberOfExecutiveBoard contextRef="ctx35" xml:lang="da">Kim Stratton</cmn:NameAndSurnameOfMemberOfExecutiveBoard>
<cmn:TitleOfMemberOfExecutiveBoard contextRef="ctx35" xml:lang="da">Chief Executive Officer</cmn:TitleOfMemberOfExecutiveBoard>
<cmn:NameAndSurnameOfMemberOfExecutiveBoard contextRef="ctx36" xml:lang="da">Anders Vadsholt</cmn:NameAndSurnameOfMemberOfExecutiveBoard>
<cmn:TitleOfMemberOfExecutiveBoard contextRef="ctx36" xml:lang="da">Chief Financial Officer</cmn:TitleOfMemberOfExecutiveBoard>
<cmn:NameOfAuditFirm contextRef="ctx37" xml:lang="da">Ernst & Young Godkendt Revisionspartnerselskab</cmn:NameOfAuditFirm>
<gsd:AddressOfAuditorStreetName contextRef="ctx37" xml:lang="da">Dirch Passers Allé</gsd:AddressOfAuditorStreetName>
<gsd:AddressOfAuditorStreetBuildingIdentifier contextRef="ctx37" xml:lang="da">36</gsd:AddressOfAuditorStreetBuildingIdentifier>
<gsd:AddressOfAuditorPostCodeIdentifier contextRef="ctx37" xml:lang="da">DK-2000</gsd:AddressOfAuditorPostCodeIdentifier>
<gsd:AddressOfAuditorDistrictName contextRef="ctx37" xml:lang="da">Frederiksberg</gsd:AddressOfAuditorDistrictName>
<cmn:IdentificationNumberCvrOfAuditFirm contextRef="ctx37">30700228</cmn:IdentificationNumberCvrOfAuditFirm>
<cmn:NameAndSurnameOfAuditor contextRef="ctx37" xml:lang="da">Christian Schwenn Johansen</cmn:NameAndSurnameOfAuditor>
<cmn:DescriptionOfAuditor contextRef="ctx37" xml:lang="da">State Authorised Public Accountant</cmn:DescriptionOfAuditor>
<arr:IdentificationNumberOfAuditor contextRef="ctx37">mne33234</arr:IdentificationNumberOfAuditor>
<cmn:NameAndSurnameOfAuditor contextRef="ctx38" xml:lang="da">Rasmus Bloch Jespersen</cmn:NameAndSurnameOfAuditor>
<cmn:DescriptionOfAuditor contextRef="ctx38" xml:lang="da">State Authorised Public Accountant</cmn:DescriptionOfAuditor>
<arr:IdentificationNumberOfAuditor contextRef="ctx38">mne35503</arr:IdentificationNumberOfAuditor>
<cmn:IdentificationNumberCvrOfAuditFirm contextRef="ctx38">30700228</cmn:IdentificationNumberCvrOfAuditFirm>
<cmn:NameOfAuditFirm contextRef="ctx38" xml:lang="da">Ernst & Young Godkendt Revisionspartnerselskab</cmn:NameOfAuditFirm>
</xbrli:xbrl>